METASTATIC BREAST CANCER
Clinical trials for METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising breast cancer drug trial halted after only two patients enrolled
Disease control TerminatedThis study tested a drug called trastuzumab deruxtecan (T-DXd) in people with advanced HER2-positive breast cancer that had stopped responding to standard therapy. The goal was to see if the drug could shrink tumors and improve quality of life. However, the trial was stopped earl…
Matched conditions: METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Spanish Breast Cancer Research Group • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New hope for Hard-to-Treat breast cancer? study cut short
Disease control TerminatedThis study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with several therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink tu…
Matched conditions: METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Cancer drug trial halted early: ixabepilone fails to show promise in advanced breast cancer
Disease control TerminatedThis study tested the chemotherapy drug ixabepilone in 13 people with advanced or metastatic breast cancer whose disease had stopped responding to two common types of chemotherapy (anthracyclines and taxanes). The goal was to see if the drug could shrink tumors or slow the cancer…
Matched conditions: METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Allarity Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Promising breast cancer drug trial halted early
Disease control TerminatedThis study tested a drug called TAS-120 (futibatinib) in people with advanced breast cancer that has a specific genetic change (FGFR amplification). The drug was given alone or with hormone therapy (fulvestrant). The trial aimed to see if tumors shrank or stopped growing. However…
Matched conditions: METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
Scientists investigate immune cells in advanced breast cancer
Knowledge-focused TerminatedThis study looked at immune cells in the blood and tumors of people with advanced breast cancer. The goal was to understand how the immune system responds to the disease. No new treatments were tested; researchers simply collected samples to learn more.
Matched conditions: METASTATIC BREAST CANCER
Sponsor: Spanish Breast Cancer Research Group • Aim: Knowledge-focused
Last updated May 17, 2026 00:59 UTC